Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Randomized double-blind placebo-controlled study of Praluent on neurocognitive function in high-risk hypercholesterolemia
MOH_2017-01-30_000071Phase 4Completed
- Sponsor
- Regeneron Pharmaceuticals
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in heterozygous familial hypercholesterolemia (HeFH) and hypercholesterolemia comparing Praluent + usual lipid-lowering therapy with Placebo + usual lipid-lowering therapy (2 arms). Primary endpoint: Neurocognitive function at 96 weeks. Started Dec 2016; status: completed.
02
Drugs
alirocumab
03
Conditions
heterozygous familial hypercholesterolemia (HeFH)hypercholesterolemia
Beyond the preview
Go deeper on MOH_2017-01-30_000071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2017-01-30_000071.